RESERPINE - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for reserpine and what is the scope of freedom to operate?

Reserpine is the generic ingredient in thirteen branded drugs marketed by Novartis, Lilly, Bowman Pharms, Bristol Myers Squibb, Barr, Bell Pharma, Bundy, Cycle, Elkins Sinn, Everylife, Halsey, Hikma, Impax Labs, Ivax Sub Teva Pharms, Marshall Pharma, Mk Labs, Mylan, Pharmavite, Purepac Pharm, Pvt Form, Rexall, Sandoz, Solvay, Tablicaps, Teva, Valeant Pharm Intl, Watson Labs, Whiteworth Town Plsn, Lannett, Panray, Vale, Vitarine, Sanofi Aventis Us, and Schering, and is included in forty-three NDAs. Additional information is available in the individual branded drug profile pages.

Summary for RESERPINE

US Patents:	0
Tradenames:	13
Applicants:	34
NDAs:	43
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	14
Patent Applications:	6,237
DailyMed Link:	RESERPINE at DailyMed

Recent Clinical Trials for RESERPINE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Zeng Changhao	NA
Mansoura University	Phase 4
Mayo Clinic	Phase 1

See all RESERPINE clinical trials

Medical Subject Heading (MeSH) Categories for RESERPINE

Adrenergic Uptake Inhibitors

Antihypertensive Agents

Antipsychotic Agents

Anatomical Therapeutic Chemical (ATC) Classes for RESERPINE

C02AA	Rauwolfia alkaloids
C02A	ANTIADRENERGIC AGENTS, CENTRALLY ACTING
C02	ANTIHYPERTENSIVES
C	Cardiovascular system

US Patents and Regulatory Information for RESERPINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Watson Labs	RESERPINE	reserpine	TABLET;ORAL	080679-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Hikma	RESERPINE	reserpine	TABLET;ORAL	080975-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Everylife	RESERPINE	reserpine	TABLET;ORAL	010441-002	Approved Prior to Jan 1, 1982		DISCN	No	No

Reserpine Market Dynamics, Financial Trajectory, Patent Status, and Generic Competition

Last updated: September 28, 2026

Reserpine is a legacy antihypertensive with no meaningful branded market, no material current patent protection, and limited commercial value. Its therapeutic role declined after beta blockers, thiazide diuretics, ACE inhibitors, angiotensin-receptor blockers, calcium-channel blockers, and newer fixed-dose combinations became standard hypertension treatments. Current demand is likely confined to low-volume generic, institutional, research, and selected international markets.

What is the current market status of reserpine?

Reserpine is an older sympatholytic drug derived from Rauwolfia alkaloids. It lowers blood pressure by depleting catecholamines and serotonin from peripheral and central storage sites. The mechanism produces antihypertensive effects but also creates tolerability concerns, including depression, sedation, nasal congestion, gastrointestinal effects, bradycardia, and orthostatic hypotension.

Reserpine tablets have historically been available in 0.1 mg and 0.25 mg strengths. Combination products containing reserpine and hydrochlorothiazide were also marketed. The former U.S. brand Serpasil is no longer a commercially important product.

The commercial market is characterized by:

Market factor	Current assessment
Branded sales	Negligible or absent in the United States
Generic competition	Limited-volume, price-driven supply
Primary demand	Legacy prescriptions, institutional use, and certain international markets
Reimbursement leverage	Low
Pricing power	Minimal
Patent protection	No material active composition or formulation estate expected
Biosimilar exposure	Not applicable; reserpine is a small-molecule drug
Regulatory barrier	Manufacturing, quality, and supply continuity rather than exclusivity
Investment profile	Low commercial upside and limited strategic value

Public company filings generally do not report reserpine revenue separately. Any sales are likely aggregated within broader generic portfolios and are immaterial to the revenues of major pharmaceutical manufacturers.

When did reserpine lose market exclusivity?

Reserpine lost practical exclusivity decades ago. It entered clinical use in the 1950s, when hypertension treatment was still developing and Rauwolfia products had a larger role. Any early composition, extraction, or product patents would have expired many years ago under modern patent-term calculations.

The product is now a mature generic drug. Its commercial decline was driven less by a single patent-expiration event than by therapeutic substitution:

1. Thiazide diuretics became widely adopted.
2. Beta blockers and calcium-channel blockers expanded treatment options.
3. ACE inhibitors and angiotensin-receptor blockers became preferred for many patients.
4. Modern guidelines emphasized drugs with stronger outcome data and better tolerability.
5. Physicians reduced use because of central nervous system and cardiovascular adverse effects.

The relevant exclusivity timeline is therefore historical rather than prospective.

Period	Market development
1950s	Reserpine entered hypertension treatment and was marketed under branded products
1960s-1970s	Broader antihypertensive classes reduced dependence on Rauwolfia drugs
1980s-1990s	Generic availability and clinical substitution accelerated decline
2000s-present	Reserpine became a niche generic with limited routine use

What patents protect reserpine products?

No commercially significant active U.S. patent estate is associated with reserpine today. Historical patents covering reserpine itself, Rauwolfia extraction, early formulations, or combination antihypertensive products would be expired.

The relevant intellectual-property categories are:

Patent category	Current commercial relevance
Reserpine composition patents	Expired
Rauwolfia extraction patents	Expired or commercially obsolete
Immediate-release tablet patents	Expired
Reserpine-hydrochlorothiazide combinations	Expired
New salt or polymorph claims	No established market significance
Controlled-release formulations	No major marketed product identified
Method-of-use patents	No material exclusivity expected
Manufacturing know-how	Potentially relevant, but not a market-blocking patent barrier

A modern entrant would therefore face little patent risk but also little economic incentive. The principal barriers would be the cost of reactivating or maintaining a compliant supply chain, validating analytical methods, securing active pharmaceutical ingredient supply, and meeting current manufacturing standards.

What is the Orange Book status of reserpine?

Reserpine does not have a meaningful current Orange Book exclusivity position. The FDA Orange Book is primarily relevant to approved drug products with active abbreviated new drug application listings and associated patents or exclusivity claims. Reserpine's market status is that of an old generic product rather than a protected reference product.

Historical reserpine products may appear in FDA archival or discontinued-product records, depending on the product and database. A discontinued product is not necessarily withdrawn for safety reasons. FDA records distinguish between commercial discontinuation and withdrawal based on safety or effectiveness concerns.[1]

The practical regulatory conclusions are:

• No current branded reference product drives market pricing.
• No active patent listing is expected to prevent generic entry.
• Any future applicant would likely rely on an abbreviated or established-product pathway, subject to FDA eligibility and product-specific requirements.
• The principal FDA risk would be product quality, manufacturing consistency, labeling, and supply continuity.

Are there Paragraph IV challenges for reserpine?

Paragraph IV litigation is not a material current issue for reserpine. Paragraph IV certifications are economically attractive when a generic applicant challenges active patents protecting a high-value branded product. Reserpine has no comparable branded revenue base or active patent wall.

A generic applicant seeking to market reserpine would more likely address:

• Whether an approved reference listed drug is available for the proposed strength and dosage form.
• Whether the product must use an abbreviated new drug application or another FDA pathway.
• Bioequivalence requirements for low-dose tablets.
• Dissolution and assay validation.
• Availability and quality of reserpine active pharmaceutical ingredient.
• Current labeling and safety-monitoring requirements.

The absence of significant Paragraph IV activity reflects the drug's maturity and low expected return, not a strong patent position held by an incumbent.

What formulation patents protect reserpine?

No formulation patent category currently appears capable of supporting premium pricing for conventional reserpine tablets. Standard immediate-release tablets are technically straightforward and have long been available.

Potential formulation opportunities could include:

• Modified-release tablets designed to reduce peak-related adverse effects.
• Combination tablets with a thiazide diuretic or another antihypertensive.
• Lower-dose products intended to reduce sedation, depression, or bradycardia.
• Improved stability formulations.
• Fixed-dose products for markets where low-cost legacy therapy remains common.

These concepts would face substantial commercial constraints. Any new formulation would need clinical and regulatory differentiation, not merely patent protection. A formulation patent without evidence of improved adherence, safety, or blood-pressure outcomes would have limited reimbursement value.

How strong is the reserpine patent estate?

The reserpine patent estate is commercially weak. Its strength can be assessed across five dimensions:

Dimension	Assessment
Composition protection	None of practical current value
Formulation protection	Limited or absent
Method-of-use protection	Limited or absent
Manufacturing protection	Possible process know-how, but low blocking power
Litigation leverage	Very low

The drug's remaining defensibility is operational rather than legal. A supplier with a qualified manufacturing process, dependable API sourcing, regulatory files, and established distribution could maintain share despite the absence of patent exclusivity. That advantage would be vulnerable to price competition and supply interruptions.

Which companies are challenging or competing with reserpine?

There is no prominent current company-led patent challenge against reserpine. Competition comes from therapeutic substitutes and generic manufacturers rather than named patent challengers.

The main substitute classes are:

Drug class	Commercial position versus reserpine
Thiazide and thiazide-like diuretics	Low-cost, widely used first-line options
ACE inhibitors	Established outcome data and broad indications
Angiotensin-receptor blockers	Strong tolerability and extensive use
Calcium-channel blockers	Widely used for uncomplicated hypertension
Beta blockers	Important in selected cardiovascular indications
Mineralocorticoid antagonists	Used in resistant hypertension and heart failure
Central sympatholytics	Generally reserved for selected cases because of tolerability

Generic manufacturers may produce reserpine as part of broad portfolios, but no major company has a strong commercial incentive to build a dedicated franchise around it. The competitive threat is substitution, not direct patent litigation.

What FDA regulatory status does reserpine have?

Reserpine has a long history of U.S. medical use, but its current commercial status is fragmented. Product availability can vary by manufacturer, strength, country, and regulatory database.

The drug's regulatory profile is shaped by:

• Mature generic status.
• Low-dose tablet manufacturing requirements.
• Known psychiatric and cardiovascular adverse effects.
• Limited use in contemporary hypertension guidelines.
• Potential need for updated labeling and pharmacovigilance.
• Variable availability of an active, commercially supported product.

Reserpine is not a biologic and has no biosimilar pathway. The relevant FDA framework is the small-molecule generic pathway, not abbreviated biologics licensing.

What patent litigation and settlement agreements affect reserpine?

No material current U.S. patent litigation or settlement agreement is associated with reserpine. The drug lacks the commercial conditions that typically generate Hatch-Waxman disputes: a high-revenue reference product, active Orange Book patents, multiple generic challengers, and a meaningful launch-at-risk decision.

Historical litigation involving reserpine, Rauwolfia products, or combination antihypertensives would have limited relevance to present commercial planning because the underlying exclusivity periods have expired.

How does reserpine compare with modern antihypertensive drugs?

Reserpine's low acquisition cost does not offset its weak commercial position. Modern alternatives have larger clinical evidence bases, broader guideline support, and better tolerability profiles.

Attribute	Reserpine	Modern first-line antihypertensives
Cost	Potentially very low	Low to moderate, depending on class
Patent exposure	Minimal	Usually expired for core molecules
Guideline position	Limited	Strong for several classes
CNS adverse effects	Important concern	Generally lower for first-line agents
Market demand	Niche	Large and recurring
Generic supply	Potentially fragmented	Deep supplier base
Commercial growth	Unlikely	Stable or class-dependent
Differentiation opportunity	Limited	Combination, adherence, and specialty indications

What revenue exposure does reserpine create?

For pharmaceutical companies, direct revenue exposure to reserpine is likely immaterial. The drug could matter operationally in three situations:

1. A manufacturer has a concentrated legacy-generic portfolio.
2. A public-health or institutional customer requires continued supply.
3. A distributor experiences a shortage and temporarily increases purchasing.

There is no credible basis for treating reserpine as a growth asset. Revenue would likely remain low, price-sensitive, and vulnerable to discontinuation. Any financial value would come from portfolio efficiency, contract supply, or niche geographic demand rather than volume expansion.

What generic launch scenarios exist for reserpine?

A new generic launch would face low legal risk but uncertain commercial returns.

Scenario 1: Conventional U.S. tablet launch

A manufacturer could pursue a standard low-dose tablet if an acceptable regulatory pathway and reference product are available. The principal risks would be small market size, pharmacy substitution, and API sourcing.

Scenario 2: International low-cost supply

Markets with continued use of Rauwolfia-derived antihypertensives could support modest demand. Regulatory requirements, local pricing controls, and procurement tenders would determine viability.

Scenario 3: Combination-product repositioning

A reserpine combination could be differentiated through convenience or local treatment practice. This strategy would require evidence that the combination retains clinical demand despite the drug's adverse-effect profile.

Scenario 4: No launch

This is the most commercially rational outcome for many manufacturers. The opportunity cost of regulatory maintenance and commercial infrastructure may exceed expected sales.

What manufacturing and intellectual-property barriers remain?

Manufacturing barriers are more important than patent barriers. Reserpine is a potent, low-dose active ingredient, so dose uniformity, content uniformity, assay sensitivity, impurity control, and dissolution performance require careful validation. API supply may be less robust than for high-volume antihypertensives.

Potential manufacturing risks include:

• Limited qualified API suppliers.
• Low batch volumes and poor economies of scale.
• Stability and degradation control.
• Accurate low-dose blending.
• Supplier qualification and change-control requirements.
• Discontinuation risk if a manufacturer exits the market.

These factors can create temporary supply constraints without creating durable pricing power.

Key Takeaways

• Reserpine is a mature, low-volume generic antihypertensive with negligible branded-market relevance.
• Its practical exclusivity ended decades ago.
• No material active patent estate, Orange Book patent position, or Paragraph IV dispute is associated with the drug today.
• Biosimilar risk does not apply because reserpine is a small-molecule drug.
• Formulation and method-of-use opportunities are technically possible but commercially weak.
• Modern antihypertensive classes have displaced reserpine because of stronger guideline support and better tolerability.
• Revenue is likely immaterial and is not separately reported by major pharmaceutical companies.
• Manufacturing continuity, API sourcing, and regulatory maintenance are the primary barriers.
• A generic launch would carry low patent risk but also limited expected financial return.

FAQs

Is reserpine still prescribed for high blood pressure?

Yes, but use is limited compared with modern antihypertensive classes. It may remain available in selected markets and clinical settings, particularly where low acquisition cost is important.

Is reserpine a controlled substance?

Reserpine is not generally treated as a controlled substance under standard U.S. controlled-substance scheduling. Its principal restrictions arise from prescription-drug regulation and safety considerations.

Can a company obtain a new patent on reserpine?

A new patent could potentially cover a genuinely novel formulation, manufacturing process, combination, or therapeutic use. The claims would need to satisfy novelty, non-obviousness, written-description, and enablement requirements. A patent on reserpine itself would not be available merely because the compound is old.

Why did reserpine decline commercially?

Its use declined because of depression and other central nervous system effects, bradycardia, limited modern guideline support, and the availability of better-tolerated antihypertensive alternatives.

Is reserpine included in the WHO Model List of Essential Medicines?

Reserpine is not generally treated as a core modern first-line antihypertensive in current international treatment frameworks. National formularies may differ based on local cost, availability, and historical prescribing practices.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

2. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. National Library of Medicine. (2024). DailyMed: Reserpine drug labeling. https://dailymed.nlm.nih.gov/dailymed/

4. Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., MacLaughlin, E. J., Muntner, P., Ovbiagele, B., Smith, S. C., Spencer, C. C., Stafford, R. S., Taler, S. J., Thomas, R. J., Williams, K. A., Williamson, J. D., & Wright, J. T. (2018). 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension, 71(6), e13-e115. https://doi.org/10.1161/HYP.0000000000000065

5. World Health Organization. (2023). WHO model list of essential medicines, 23rd list. https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.02